Moderna (MRNA) stock tumbled Wednesday after the company said its newly approved RSV vaccine was only about 50% effective after 18 months — paling in comparison to rivals from Pfizer (PFE) and GSK (GSK).
↑
X
CRSP Stock On Wild Ride After FDA’s Historic Approval. These Gene Editing Treatments Could Come Next.
Respiratory syncytial virus, or RSV, causes coldlike symptoms in most people. But it can be serious or deadly in newborns and older adults.
After 18 months, Moderna’s vaccine proved 49.9% to 50.3% effective against multiple symptoms of lower respiratory tract disease.
In comparison, GSK said its vaccine, Arexvy, was 78.6% effective against severe RSV after two years. Similarly, Pfizer’s Abrysvo was 77.8% effective midway through a second season on the market.
Moderna stock toppled more than 6% to 129.04 in midday trading on today’s stock market. Pfizer stock also fell a fraction to 27.85, while GSK stock rose 0.5% to 40.49.
More to follow.
Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Why United Therapeutics, An IBD 50 Stock, Has Surged 36% Over Nine Weeks
How IBD Stock Of The Day Blueprint Medicines ‘Knocked It Out Of The Park’
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
Want More IBD Insights? Subscribe To Our Investing Podcast!
Find The Best Long-Term Investments With IBD Long-Term Leaders
Signup bonus from
